Phase 1 clinical trials in end-stage cancer: Patient understanding of trial premises and motives for participation

Supportive Care in Cancer

Volumn 21, Issue 11, 2013, Pages 3137-3142

  Godskesen, Tove ^a   Nygren, Peter ^a   Nordin, Karin ^b,c   Hansson, Mats ^a   Kihlbom, Ulrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cancer; Clinical trials; Ethics; Sweden

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTENT ANALYSIS; COPING BEHAVIOR; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; EMOTIONAL STRESS; EXPECTATION; EXPLORATORY RESEARCH; FEMALE; HEALTH SURVEY; HUMAN; LUNG CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ETHICS; MELANOMA; MOTIVATION; PANCREAS CANCER; PATIENT ATTITUDE; PATIENT INFORMATION; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL WELL BEING; QUALITATIVE RESEARCH; RISK BENEFIT ANALYSIS; SOCIAL SUPPORT;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MOTIVATION; NEOPLASMS; PATIENT PARTICIPATION; QUALITATIVE RESEARCH; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL; SWEDEN;

EID: 84885581715     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1891-7     Document Type: Article

References (28)

1. Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5:319-329
2. Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, New York
3. Cohen L, de Moor C, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91:1949-1955
4. Cox K (2000) Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants' experiences. Psychooncol 9:314-322
5. Cox K (2002) Informed consent and decision-making: patients' experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46:31-38
6. Daugherty CK (1999) Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 17:1601-1617
7. Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6-14
8. Eriksson K (2001) Vårdvetenskap som akademisk disciplin. (Health care science as an academic discipline). Åbo Akademi University, Turku
9. Fussenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152-1160
10. Grady C (2005) Payment of clinical research subjects. J Clin Invest 115:1681-1687
11. Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105-112
12. Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Brit J Cancer 89:1166-1171
13. Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134-2140
14. Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787-792
15. Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29:61-68
16. Kahneman D, Tversky A (1979) Prospect theory - analysis of decision under risk. Econometrica 47:263-291
17. Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3:57-68
18. Kvale S (1997) Den kvalitativa forskningsintervjun. Studentlitteratur, Lund
19. Kvale S (2007) Doing interviews. Sage, Thousand Oaks
20. Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5:65-72
21. Mcgraw JG (1995) Loneliness, its nature and forms - an existential perspective. Man World 28:43-64
22. Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol 21:2589-2596
23. Moore S (2001) A need to try everything: patient participation in phase I trials. J Adv Nurs 33:738-747
24. Ohlen J (2002) Practical wisdom: competencies required in alleviating suffering in palliative care. J Palliat Care 18:293-299
25. Patton MQ (2002) Qualitative research and evaluation methods. Sage, London
26. Saeteren B, Lindstrom UA, Naden D (2011) Latching onto life: living in the area of tension between the possibility of life and the necessity of death. J Clin Nurs 20:811-818
27. Stolberg SG (2000) Teenager's death is shaking up field of human gene-therapy experiments. New York Times, New York
28. Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP (2010) The culture of faith and hope patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116:3702-3711